Movement Analysis: Edgewise experienced a significant decline on September 23 due to high-level correction, overvaluation, and intensified competition.

1. On September 17, 2026, Edgewise's share price reached an all-time high, after which short-term trading momentum cooled down; as of September 23, 2026, the stock had fallen a cumulative 8.52% over the past five days, though it remains up 67.52% year-to-date, indicating pressure for a high-level pullback.
2. As of July 21, 2026, the company is still in a pre-revenue and continuous loss stage, with a price-to-book ratio of about 8.5, signaling a relatively high valuation. The fundamental realization still depends on subsequent clinical and commercialization progress of EDG-7500.
3. On September 2 and September 4, 2026, competing products aficamten and mavacamten announced expansion of indications and long-term efficacy updates. Competition in the HCM market is intensifying, which may suppress valuation expectations for the commercial outlook of EDG-7500.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only and does not constitute investment advice.)